Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18788285 | 0.91 | ALDH1A1 (0.45) | ALDH1A1TSHRTP53GAAEPHX2 | |
| SCHEMBL25921180 | 0.91 | ALDH1A1 (0.45) | ALDH1A1TSHRTP53GAAEPHX2 | |
| SCHEMBL28616847 | 0.89 | ALDH1A1 (0.50) | ALDH1A1TSHRTP53GAAEPHX2 | |
| SCHEMBL2953187 | 0.87 | ALDH1A1 (0.42) | ALDH1A1TSHRTP53GAAEPHX2 | |
| SCHEMBL13986867 | 0.87 | TSHR (0.68) | ALDH1A1TSHRTP53EPHX2MEN1 | |
| SCHEMBL29187635 | 0.82 | ALDH1A1 (0.68) | ALDH1A1TSHRTP53MEN1THRB | |
| SCHEMBL8465180 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TSHRTP53GAAEPHX2 | |
| SCHEMBL814157 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TSHRTP53GAAEPHX2 | |
| SCHEMBL10425067 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TSHRTP53EPHX2THRB | |
| SCHEMBL496221 | 0.81 | TSHR (0.72) | ALDH1A1TSHRTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110240629-B | Protein degradation targeting BCR-ABL compound and antitumor application thereof | 上海科技大学 | 2023-10-03 | — | — | CN | disclosed |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | SHANGHAITECH UNIVERSITY (CN) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | CRBN, VHL, CBL | ALDH1A1 589/4885TSHR 4223/4885TP53 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.